Packages of weight loss drugs Wegovy, Ozempic and Mounjaro.
Picture Alliance | Getty Images
The growing demand for diabetes and weight loss drugs like Mounjaro, Ozempic and Wegovy has helped fuel higher health costs for large employers. For many, the big question is whether the pricy medications known as GLP-1s will pay off by improving worker health and lowering overall health costs over time. Analysts at Aon say it’s already happening.
“We’ve never seen anything like this, really,” said Greg Case, CEO of Aon, an employer benefits services firm. “There was a 44% reduction in major cardiovascular issues. There was substantial reduction in osteoporosis. There was substantial reduction in pneumonia of multiple types.”
Aon researchers found that within two years, improved health outcomes for patients who were taking GLP-1 drugs bends the cost curve on medical care for them and their employers. However, getting to those savings requires high upfront costs.
GLP-1s come at a list price of more than $1,000 per dose. As broader approval for the drugs spurs higher demand, it’s also causing employer drug spending to spike. Since 2023, GLP-1s have pushed costs up at a pace than high-priced specialty medications, which include costly cancer and autoimmune treatments, according to an analysis by Evernorth, a division of Cigna.
Aon analysts looked at medical claims data for 139,000 U.S.-based workers with employer health coverage who took GLP-1 medications between 2022 and 2024. Beyond the drug costs, the study found GLP-1 patients tend to incur higher medical costs in their first year on the drugs, with more doctor visits to monitor their treatment on the drug and to seek help for other issues such as sleep apnea and esophageal conditions like acid reflux.
“The increase comes about in the first 12 to 15 months,” Case said. “They’re getting remedies on things that actually are underlying conditions [of obesity].”
But by the end of the second year of treatment with the GLP-1 drugs, overall health care costs for patients taking them fell 7% on average, compared to workers with similar chronic conditions and obesity characteristics who were not taking the drugs, Aon found. For GLP-1 patients who maintained rigorous adherence to the drug regimen, the savings were up to 13%.
The biggest driver of those savings was the reduction by more than 40% of major adverse cardiac events such as heart attacks and strokes, compared to patients who were not taking the drugs, as well as a reduction in the onset of diabetes.
Case said with this data, Aon has been able to help clients understand the timeline for seeing a return on providing insurance coverage for GLP-1s for weight loss, in addition to Type 2 Diabetes.
“We saw every single place where the cost went down — and it’s stunning,” said Case. “You can do this in a way that has an ROI, that will literally be an economic return.”
Following its research, Aon has launched a subsidized GLP-1 weight management program for its own U.S. workforce, which includes weekly virtual wellness visits and home blood tests to help employees adhere to the drug regimen.
The company will present the full results of its study at the Milken Institute Global Conference on Monday.
